Clinical Trials Directory

Trials / Completed

CompletedNCT07148037

Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population

Effect of SLC01B1 (rs4149056) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population

Status
Completed
Phase
Study type
Observational
Enrollment
150 (actual)
Sponsor
Riphah International University · Academic / Other
Sex
All
Age
40 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The goal of this prospective cohort study was to identify the effect of SLC01B1 gene polymorphism in the Pakistani population. The main questions it aims to answer are: To identify polymorphism in SLOC1B1 (rs4149056) in the Pakistani population. To determine the association between SLOC1B1 (rs4149056) polymorphism and the clinical efficacy of atorvastatin To determine the association between SLOC1B1 (rs4149056) polymorphism and the tolerability of atorvastatin

Detailed description

The goal of this prospective cohort study was to identify the effect of SLC01B1 gene polymorphism in the Pakistani population, due to the high prevalence of this variant in the Pakistani Population The main questions it aims to answer are: To identify polymorphism in SLOC1B1 (rs4149056) in the Pakistani population. To determine the association between SLOC1B1 (rs4149056) polymorphism and the clinical efficacy of atorvastatin To determine the association between SLOC1B1 (rs4149056) polymorphism and tolerability of atorvastatin. The participants' blood samples were taken and further genotyping was performed using conventional tetra ARMS PCR. The results were visualized by gel electrophoresis.

Conditions

Interventions

TypeNameDescription
GENETICAtorvastatin10mg once a day for 2 months

Timeline

Start date
2024-09-01
Primary completion
2025-07-31
Completion
2025-07-31
First posted
2025-08-29
Last updated
2025-08-29

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07148037. Inclusion in this directory is not an endorsement.